Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience.
COVID-19
convalescent plasma
mortality
safety
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
20
02
2022
revised:
07
03
2022
accepted:
11
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80−320). Their median age was 68 years (IQR, 56−78 years), and 62% were males. At enrollment, 55% of patients had an increased body mass index (BMI), and 25.6% had at least three comorbidities. The 28-day crude mortality rate was 12.6% (51/405). Young age (<68 years), mild disease (admission to low-intensity departments) and early treatment (<7 days from symptoms onset) with high nAb titer (≥320) CCP were found as independently associated with a favorable response to CCP treatment. No safety concerns were recorded, with a rate of CCP-related adverse reactions (all of mild intensity) of 1.3%. In our real-life experience, the first in the western world, early administration of high-titer CCP was a safe and effective treatment for hospitalized COVID-19 patients.
Identifiants
pubmed: 35330170
pii: life12030420
doi: 10.3390/life12030420
pmc: PMC8950373
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Transfus Apher Sci. 2020 Aug;59(4):102817
pubmed: 32532691
PLoS Med. 2021 Dec 20;18(12):e1003872
pubmed: 34928960
Epidemiol Prev. 2021 Nov-Dec;45(6):559-567
pubmed: 35001599
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Microbiol Newsl. 2021 Feb 15;43(4):23-32
pubmed: 33564204
Vox Sang. 2021 Feb;116(2):249-250
pubmed: 32950039
Clin Microbiol Rev. 2022 Mar 9;:e0020021
pubmed: 35262370
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34464358
Pharmaceuticals (Basel). 2021 May 28;14(6):
pubmed: 34071185
Vox Sang. 2021 Oct;116(9):935-942
pubmed: 33794556
Intern Emerg Med. 2020 Aug;15(5):819-824
pubmed: 32468508
Eur J Intern Med. 2022 Mar;97:42-49
pubmed: 34980505
Clin Chem Lab Med. 2021 Sep 02;60(1):e4-e6
pubmed: 34472761
Vox Sang. 2021 Jan;116(1):136-137
pubmed: 32324899
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Transfusion. 2021 Mar;61(3):830-838
pubmed: 33231325
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Infect Prev Pract. 2020 Sep;2(3):100061
pubmed: 34316558
Mayo Clin Proc Innov Qual Outcomes. 2021 Apr;5(2):403-412
pubmed: 33585799
Blood Transfus. 2021 Jul;19(4):317-326
pubmed: 34059188
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Haematologica. 2020 Jul 23;105(12):2834-2840
pubmed: 33256382
Diagnostics (Basel). 2021 Sep 11;11(9):
pubmed: 34574004
Life (Basel). 2021 Apr 18;11(4):
pubmed: 33919577
Mayo Clin Proc. 2021 Aug;96(8):2279-2281
pubmed: 34353475
Elife. 2021 Jun 04;10:
pubmed: 34085928
Blood Adv. 2021 Mar 9;5(5):1305-1309
pubmed: 33656534
Mayo Clin Proc. 2021 May;96(5):1368-1369
pubmed: 33958067